Effectiveness of a Brain-Computer Interface Based Programme for the Treatment of ADHD: A Pilot Study
By Choon Guan Lim, Tih-Shih Lee, Cuntai Guan, Daniel Shuen Sheng Fung, Yin Bun Cheung, Stephanie Sze Wei Teng, Haihong Zhang, K Ranga Krishnan
EDITOR’S LETTER
Charles B. Nemeroff, MD, PhD
Economics of Cancer Drug Development
By Michael Dickson, PhD, and Gene Reeder, PhD
Economic Impacts of Anxiety Disorders
By Ernst R. Berndt, PhD and Tamar Sisitsky, MA
Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders
By Charles B. Nemeroff, MD, PhD
Duloxetine in Military Posttraumatic Stress Disorder
By Gerardo Villarreal, José M. Cañive, Lawrence A. Calais, Gregory Toney, Ashley K. Smith
Duloxetine for the Treatment of Major Depressive Disorder
By Charles B. Nemeroff, MD, PhD, Alan F. Schatzberg, MD, David J. Goldstein, MD, PhD, Michael J. Detke, MD, PhD, Craig Mallinckrodt, PhD, Yili Lu, PhD, and Pierre V. Tran, MD
Drug–Drug Interactions Associated with Second-Generation Antipsychotics: Considerations for Clinicians and Patients
By Robert R. Conley, MD and Deanna L. Kelly, PharmD, BCPP
COMPLICATED CASE HISTORIES
Drug Induced Mania in a Boy with High Functioning Autism
By Mustafa Deniz Tutkunkardas, Nahit Motavalli Mukaddes
Drug Development for Anxiety Disorders: New Roles for Atypical Antipsychotics
By William H. Carson, MD, Hisashi Kitagawa, PhD, and Charles B. Nemeroff, MD, PhD
¡Bienvenidos a
Psiquiatría y Salud Integral!
Dr. Juan E. Mezzich y Dr. Miguel R. Jorge